The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Open accessAbstract
Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non–small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti–PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [86]
In the citing paper
“This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [86]
In the citing paper
“other features such as TMB appear to also be associated with clinical benefit to PD-1 / PD-L1 antibodies”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [27]
In the citing paper
“The predictive value of TMB, MSI, and dMMR as biomarkers of response to ICBs has been supported by several studies”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Rizvi et al., 2015
In the citing paper
“also shown to be true for PD- 1 blockade in NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Rizvi et al., 2015
In the citing paper
“Previous reports have shown that the total number of somatic coding mutations in a cancer genome correlates with response to ICB (7, 8, 10–12, 17).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [10]
In the citing paper
“Another well-recognized biomarker that predicts response or nonresponse to ICIs is the mutational burden of the tumor, with higher tumor mutational loads strongly associated with response to both anti-CTLA-4 and anti-PD-1 across multiple cancer indications (83)(84)(85)(86).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationA method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Flagged first, then by citations
Research works printed but not linked: 1
- Hindges R., Hübscher U., DNA polymerase delta, an essential enzyme for DNA transactions. Biol. Chem. 378, 345–362 (1997).9191022
Cited by
Sorted by citations
Items 601–700 of 1,053
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J., O’Toole, S. A., Anderson, L. A., Scolyer, R. A., et al. (2020) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 252
Gene aberrations for precision medicine against lung adenocarcinoma
Saito, M., Shiraishi, K., Kunitoh, H., Takenoshita, S., Yokota, J., & Kohno, T. (2016) · Cancer Science · doi:10.1111/cas.12941 · Cited by 249
Palmer, C. D., Rappaport, A., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01937-6 · Cited by 257
Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
Kager, L., Tamamyan, G., & Bielack, S. (2016) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 242
Sex-associated molecular differences for cancer immunotherapy
Ye, Y., Jing, Y., Liang, L., Mills, G. B., Diao, L., Liu, H., & Han, L. (2020) · Nature Communications · doi:10.1038/s41467-020-15679-x · Cited by 255
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Lhuillier, C., Rudqvist, N.-P., Yamazaki, T., Zhang, T., Charpentier, M., Galluzzi, L., Dephoure, N., Clement, C. C., Santambrogio, L., Zhou, X. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138740 · Cited by 256
Wang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241
Riess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
Genomic and evolutionary classification of lung cancer in never smokers
Zhang, T., Joubert, P., Ansari‐Pour, N., Wei, Z., Hoang, P. H., Lokanga, R. A., Moye, A. L., Rosenbaum, J., González-Pérez, A., Martínez-Jiménez, F., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00920-0 · Cited by 243
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240
Hui, R., Garon, E. B., Goldman, J. W., Leighl, N. B., Hellmann, M. D., Patnaik, A., Gandhi, L., Eder, J. P., Ahn, M., Horn, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx008 · Cited by 239
Self-citationHallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 251
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 241
Chao, Y., Liang, C., Tao, H., Du, Y., Wu, D., Dong, Z., Jin, Q., Chen, G., Xu, J., Xiao, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4204 · Cited by 239
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 242
Evolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 242
Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V. L., Esaulova, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.003 · Cited by 244
Self-citationGuibert, N. M., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.001 · Cited by 236
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Tahir, S. A., Gao, J., Miura, Y., Blando, J. M., Tidwell, R. S. S., Zhao, H., Subudhi, S. K., Tawbi, H. A., Keung, E. Z.-Y., Wargo, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908079116 · Cited by 238
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Mardiana, S., & Gill, S. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00697 · Cited by 240
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E. P., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1500 · Cited by 243
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 240
The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez‐Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 238
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 244
Chen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Campenhout, C. V., Rorive, S., Remmelink, M., Salmon, I. J., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 238
Dong, L., Peng, L., Ma, L., Liu, D., Zhang, S., Luo, S.-Z., Rao, J., Zhu, H., Yang, S., Xi, S.-J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.014 · Cited by 237
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30453-x · Cited by 232
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Biology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 230
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 237
Zhang, X., Shi, M., Chen, T., & Zhang, B. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.08.030 · Cited by 231
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Zhou, F., Qiao, M., & Zhou, C. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00577-5 · Cited by 239
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 243
Han, G., Yang, G., Hao, D., Lü, Y., Thein, K. Z., Simpson, B. S. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25894-9 · Cited by 238
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 236
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 233
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 237
Lee, J. S., & Ruppin, E. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2311 · Cited by 235
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Pietanza, M. C., Byers, L. A., Minna, J. D., & Rudin, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2958 · Cited by 229
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J. D., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 235
Self-citationDesigning nanomedicine for immuno-oncology
Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 230
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 235
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J. D., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 233
Mino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 240
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 232
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Steuer, C. E., & Ramalingam, S. S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8770 · Cited by 228
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Li, H., Bullock, K., Gurjao, C., Braun, D., Shukla, S. A., Bossé, D., Lalani, A.-K. A., Gopal, S., Jin, C., Horak, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12361-9 · Cited by 218
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
Limagne, E., Nuttin, L., Thibaudin, M., Jacquin, É., Aucagne, R., Bon, M., Revy, S., Barnestein, R., Ballot, E., Truntzer, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.009 · Cited by 231
Campesato, L. F., Barroso‐Sousa, R., Jimenez, L., Corrêa, B., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 224
Duruisseaux, M., Martínez‐Cardús, A., Calleja-Cervantes, M. E., Morán, S., de Moura, M. C., Dávalos, V., Piñeyro, D., Sánchez‐Céspedes, M., Girard, N., Brevet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30284-4 · Cited by 231
Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L. E., Chen, J., Huang, X. F., & Chen, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 232
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M. C., Kurley, S. J., Domínguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 227
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 235
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Wang, R., & Wang, H. Y. (2016) · Cell Research · doi:10.1038/cr.2016.155 · Cited by 237
Wang, G.-Z., Zhang, L., Zhao, X.-C., Gao, S.-H., Qu, L.-W., Yu, H., Fang, W.-F., Zhou, Y.-C., Liang, F., Zhang, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08887-7 · Cited by 213
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yan, Y., Kumar, A. B., Finnes, H. D., Markovic, S. N., Park, S. S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 231
Karn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C. A., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H., Huober, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.015 · Cited by 228
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Self-citationCancer immunotherapy targeting neoantigens
Lu, Y., & Robbins, P. F. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 225
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers
Morris, L. G. T., Chandramohan, R., West, L., Zehir, A., Chakravarty, D., Pfister, D. G., Wong, R. J., Lee, N. Y., Sherman, E. J., Baxi, S. S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1790 · Cited by 230
Self-citationHarnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 227
T cell regeneration after immunological injury
Velardi, E., Tsai, J. J., & van den Brink, M. R. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00457-z · Cited by 222
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J. L., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 221
Lu, J., Liu, X., Liao, Y., Wang, X., Ahmed, A., Jiang, W., Ji, Y. C., Meng, H., & Nel, A. E. (2018) · ACS Nano · doi:10.1021/acsnano.8b05189 · Cited by 225
RetractedPD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 227
Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 225
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 226
Genomic landscape of high-grade meningiomas
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J. A., Gibson, W. J., Agarwalla, P. K., Horowitz, P. M., Schumacher, S. E., Esaulova, E., Mei, Y., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0014-7 · Cited by 229
Soulières, D., Faivre, S. J., Mesı́a, R., Remenár, É., Li, S.-H., Karpenko, A., Dechaphunkul, A., Ochsenreither, S., Kiss, L. A., Lin, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30064-5 · Cited by 219
Caswell, D. R., & Swanton, C. (2017) · BMC Medicine · doi:10.1186/s12916-017-0900-y · Cited by 225
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 224
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 223
Best, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H., Ritchie, M. E., McConville, M. J., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.006 · Cited by 217
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
Self-citationCheckpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here
Kwa, M. J., & Adams, S. (2018) · Cancer · doi:10.1002/cncr.31272 · Cited by 216
Buder‐Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 219
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Rabbie, R., Ferguson, P. M., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2018) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 233
Checkpoint inhibitors in pancreatic cancer
Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 219
Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 218
Lu, H., Arshad, M., Thornton, A., Avesani, G., Cunnea, P., Curry, E. W., Kanavati, F., Liang, J., Nixon, K., Williams, S. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08718-9 · Cited by 213
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Dudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A., Moskovitz, M. T., Keren, S., Popovits‐Hadari, N., Urban, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.024 · Cited by 221
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G. J., Rizvi, H. A., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 230
Self-citationPARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 216
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 217
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M. T., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 216
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
Rudqvist, N.-P., Pilones, K. A., Lhuillier, C., Wennerberg, E., Sidhom, J.-W., Emerson, R., Robins, H. S., Schneck, J. P., Formenti, S. C., & Demaria, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0134 · Cited by 217
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popović, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 209
Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Complementing the Cancer-Immunity Cycle
Pı́o, R., Ajona, D., Ortiz‐Espinosa, S., Mantovani, A., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00774 · Cited by 217
Xu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Li, Y., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 219
Haanen, J. B. A. G., & Robert, C. (2015) · Progress in tumor research · doi:10.1159/000437178 · Cited by 221
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 214
Metadata
- Authors
- Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The Netherlands Cancer Institute (NL)
- Columbia University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Rizvi, Naiyer A.
- Hellmann, Matthew D.
- Snyder, Alexandra
- Chan, Timothy A.
- ORCID
- Rizvi, Naiyer A.
- Hellmann, Matthew D.
- Snyder, Alexandra
- Kvistborg, Pia
- Makarov, Vladimir
- Havel, Jonathan J.
- Lee, William
- Yuan, Jianda
- Wong, Phillip
- Miller, Martin L.
- Rekhtman, Natasha
- Moreira, Andre L.
- Gasmi, Billel
- Zappasodi, Roberta
- Sander, Chris
- Garon, Edward B.
- Merghoub, Taha
- Wolchok, Jedd D.
- Schumacher, Ton N.
- Chan, Timothy A.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 124-128
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4993154
- OpenAlex
- W2049553585
- Semantic Scholar
- d0a5bc5ff2c33c640e97009377304357fe8d2838
- Cited by
- 7,802
- References
- 68
- Citations by year
- 2026: 258 · 2025: 389 · 2024: 473 · 2023: 598 · 2022: 824 · 2021: 930 · 2020: 956 · 2019: 881 · 2018: 883 · 2017: 762 · 2016: 614 · 2015: 216
- FWCI
- 360.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Lung Cancer Research Foundation
- The STARR Foundation
- Geoffrey Beene Cancer Research Center
- Society for Memorial Sloan Kettering Cancer Center
- Frederick Adler Chair Fund
- The One Ball Matt Memorial Golf Tournament
- Queen Wilhelmina Cancer Research Award
- Ludwig Trust
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- non-small cell lung cancer, anti-PD-1 therapy, pembrolizumab, immune checkpoint inhibitors, mutational burden, non-synonymous mutations, neoantigens, CD8+ T cell responses, treatment response prediction, tumor genomic landscape
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA Repair, Humans, Lung Neoplasms, Mutation, Smoking, Cohort Studies, CD8-Positive T-Lymphocytes, Disease-Free Survival, Drug Resistance, Neoplasm, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
